secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001200375-22-000037
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q3 2022 revenue $34.5M, net loss $10.0M; reaffirms FY2022 guidance
--------------------------------------------------------------------------

- Total Q3 revenue $34.5M, down 6% YoY from $36.8M; net loss $10.0M ($0.15/share) vs net income $2.2M in Q3 2021.
- Product revenue $28.0M, down 2%; excluding COVID drug (PAXLOVID) sales, product revenue up 53% to $15.1M.
- Reiterated FY2022 guidance: total revenue $135-141M, product revenue $112-118M (incl ~$75M from Pfizer).
- New CEO Dr. Stephen Dilly, COO Kevin Norrett, GC Margaret Fitzgerald appointed; Rahul Singhvi added to Board.
- Cash and equivalents $108.7M; expects cash to fund operations through at least end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000037/0001200375-22-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000037/cdxs-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001200375-22-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer